The Efficacy and Safety of Remimazolam Besylate Combined with Esketamine for Outpatient Colonoscopy: A Prospective, Randomized, Controlled Clinical Trial
Drug Design, Development and Therapy · 2023
DOI: 10.2147/dddt.s425860 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Drug Design, Development and Therapy, 2023. Verfasst von Wei Li und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anaesthesiology, Ordos Central Hospital, Ordos, Inner Mongolia Autonomous Region, People's Republic of China. Hauptthemen laut MEDLINE: Propofol. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Purpose
Evaluate the efficacy and safety of remimazolam besylate combined with esketamine for outpatient colonoscopy. Patients and methods: A total of 150 outpatients undergoing colonoscopy were randomized into two groups. A MOAA/S score ≤3 was maintained. The primary outcome was the rate of successful colonoscopy completion. Time indicators, hemodynamic parameters, the consumption of lidocaine, esketamine, propofol and remimazolam besylate, MOAA/S scores and bispectral index (BIS) values, the lowest SpO2, body movement, the use of rescue medication, endoscopist and patient satisfaction, recall of the procedure, mini-mental state examination (MMSE), fatigue level and adverse events were recorded.
Results
Procedure completion was equivalent between groups (P > 0.05). Both induction and awakening times were significantly shorter in the P group (P 0.05). The lowest SpO2 was significantly lower in the P group, while the level of fatigue was higher (P 0.05). Both HR and RR were significantly lower in the P group from T3 to T5 (P < 0.05). BIS values were significantly lower in the P group from T3 to T5, while MOAA/S was significantly lower in the P group at T3 and T4 (P < 0.05). Pain on injection was significantly higher in the P group (P < 0.05).
Conclusion
Remimazolam besylate has a similar efficacy to propofol when combined with subanesthetic doses of esketamine during outpatient colonoscopy. Remimazolam besylate combined with esketamine resulted in less injection pain and more stable hemodynamics, although it prolonged induction and awakening time.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Anaesthesiology, Ordos Central Hospital, Ordos, Inner Mongolia Autonomous Region, People's Republic of China.
Zitieren
APA
Li, W., Zhao, J., Hao, R., Wang, S., Chen, M., Liu, H., Qi, L., & Hao, Z. (2023). The Efficacy and Safety of Remimazolam Besylate Combined with Esketamine for Outpatient Colonoscopy: A Prospective, Randomized, Controlled Clinical Trial. Drug Design, Development and Therapy. https://doi.org/10.2147/dddt.s425860
Vancouver
Li W, Zhao J, Hao R, Wang S, Chen M, Liu H, et al. The Efficacy and Safety of Remimazolam Besylate Combined with Esketamine for Outpatient Colonoscopy: A Prospective, Randomized, Controlled Clinical Trial. Drug Design, Development and Therapy. 2023. doi:10.2147/dddt.s425860
BibTeX
@article{Li2023,
author = {Li, Wei and Zhao, Jun and Hao, Ruiping and Wang, Shujuan and Chen, Ming and Liu, Huijun and Qi, Le and Hao, Zaijun},
title = {The Efficacy and Safety of Remimazolam Besylate Combined with Esketamine for Outpatient Colonoscopy: A Prospective, Randomized, Controlled Clinical Trial},
journal = {Drug Design, Development and Therapy},
year = {2023},
doi = {10.2147/dddt.s425860}
}
EUVIMED